Enfermedad pulmonar obstructiva crónica y cáncer de pulmón: Implicaciones prácticas

Archivos de Bronconeumologia

Volumn 37, Issue 5, 2001, Pages 240-247

  Diez Herranz A ^a,b  

^a Centro Médico Paracelso   (Spain)

^b Gabinete Medico Lopez Gomez   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC OBSTRUCTIVE LUNG DISEASE; HUMAN; INCIDENCE; LUNG TUMOR; PROGNOSIS; REVIEW;

HUMANS; INCIDENCE; LUNG NEOPLASMS; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 0347872821     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-2896(01)75061-2     Document Type: Review

References (93)

1. Weiss W. COPD and lung cancer. En: Cherniack NS, editor. Chronic obstructive pulmonary disease. Filadelfia: WB Saunders Company, 1991; 344-347.
2. Romero Candeira S, Picher Núñez J, Otero Ochoa L, Delgado Pérez E, Izquierdo del Amo A. Aspectos funcionales en el carcinoma broncogénico. Rev Clin Esp 1981; 161: 319-322.
3. Samet JM, Humble CG, Pathak DR. Personal and family history of respiratory disease and lung cancer risk. Am Rev Respir Dis 1986; 134: 466-470.
4. Skillrud DM, Offord KP, Miller RD. Higher risk of lung cancer in chronic obstructive pulmonary disease. A prospective, matched, controlled study. Ann Intern Med 1986; 105: 503-507.
5. Tockman MS, Anthonisen NR, Wright EC, Donthan MG, the Intermitent Positive Pressure Breathing Trial Group, and the Johns Hopkins Lung Project for the early detection of lung cancer. Airways obstruction and the risk of lung cancer. Ann Intern Med 1987; 106: 512-518.
6. Wu AH, Yu MC, Thomas DC, Pike MC, Henderson BE. Personal and family history of lung disease as risk factors for adenocarcinoma of the lung. Cancer Res 1988; 48: 7279-7284.
7. Sánchez de Cos Escuín J, Redondo Antequera J, Sever Redondo A, García Lario A, De la Cruz Ríos JL, Masa Jiménez F. Carcinoma broncopulmonar. Estudio epidemiológico-clínico de 157 casos. Aten Primaria 1989; 6: 304-311.
8. Díez Herranz A. La cirugía en el tratamiento del carcinoma broncopulmonar extendido a los ganglios mediastínicos [Tesina de licenciatura] Valladolid, 1989.
9. Lange P, Nyboe J, Appleyard M, Jensen G, Schnohr P. Ventilatory function and chronic mucus hypersecretion as predictors of death from lung cancer. Am Rev Respir Dis 1990; 141: 613-617.
10. Osann KE. Lung cancer in women: the importance of smoking, family history of cancer, and medical history of respiratory disease. Cancer Res 1991; 51: 4893-4897.
11. Alavanja MCR, Brownson RC, Boice JD Jr, Hock E. Pre-existing lung disease and lung cancer among nonsmoking women. Am J Epidemiol 1992; 136: 623-632.
12. Michils A, Yernault JC, Noel E, Gossart B, Servais G, Duchateau J. Abnormal humoral immune response to mucosal antigenic stimulation in patients with lung cancer. Cancer 1992; 69: 2252-2257.
13. Dangubic V, Ninkovic M, Popovic D, Tomic I, Ciric B, Dautovic M. The obstruction syndrome in patients with bronchogenic carcinoma [resumen]. Vojnosanit Pregl 1993; 50: 21-25.
14. Bechtel JJ, Kelley WR, Petty TL, Patz DS, Saccomanno G. Outcome of 51 patients with roentgenographically occult lung cancer detected by sputum cytologic testing: a community hospital program. Arch Intern Med 1994; 154: 975-980.
15. Wu AH, Fontham ETH, Reynolds P, Greenberg RS, Buffer P, Liff J et al. Previous lung disease and risk of lung cancer among lifetime nonsmoking women in the United States. Am J Epidemiol 1995; 141: 1023-1032.
16. Congleton J, Muers MF. The incidence of airflow obstruction in bronchogenic carcinoma, its relation to breathlessness, and response to bronchodilator therapy. Respir Med 1995; 89: 291-296.
17. Janssen-Heijnen MLG, Schipper RM, Razenberg PPA, Crommelin MA, Coebergh J-WW. Prevalence and co-morbidity in lung cancer patients and its relationship with treatment: a population based study. Lung Cancer 1998; 21: 105-113.
18. Aller Álvarez JL, De Frutos Arribas JF, Díez Herranz A, Heras Gómez F, Matilla González JM. Comorbilidad. En: Hernández Hernández JR, Heras Gómez F, Cordovilla Pérez, editores, por el Grupo de Estudio del Carcinoma Broncopulmonar de la SOCALPAR. El carcinoma broncopulmonar en la Comunidad de Castilla y León. Año 1997. Sociedad Castellano-Leonesa de Patología Respiratoria (SOCALPAR). Bilbao: CAGEGRAF/Laboratorios FAES, 2000; 81-88.
19. Anastasatu C, Morgenstern H, Burnea D, Cristea M, Mangiulea V, Prutcanu L. Risk of bronchopulmonary cancer in patients with chronic obstructive bronchopneumopathy [resumen]. Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol 1982; 31: 211-218.
20. Harber P, Oren A, Moshenifar Z, Lew M. Obstructive airways disease as a risk factor for asbestos-associated malignancy. J Occup Med 1986; 28: 82-86.
21. Peto R, Speizer FE, Cochrane AL, Moore F, Fletcher CM, Tinker CM et al. The relevance in adults of air-flow obstruction, but no of mucus hypersecretion, to mortality from chronic lung disease. Results from 20 years of prospective observation. Am Rev Respir Dis 1983; 128: 491-500.
22. Tenkanen L, Hakulinen T, Tejpo L. The joint effect of smoking and respiratory symptoms on risk of lung cancer. Int J Epidemiol 1987; 16: 509-515.
23. 1) to lung cancer mortality in the Multiple Risk Factor Intervention Trial (MRFIT). Am J Epidemiol 1990; 132: 265-274.
24. Nomura A, Stemmermann GN, Chyou PH, Marcus EB, Buist AS. Prospective study of pulmonary function and lung cancer. Am Rev Respir Dis 1991; 144: 307-311.
25. Wiles FJ, Hnizdo E. Relevance of airflow obstruction and mucus hypersecretion to mortality. Respir Med 1991; 85: 27-35.
26. Vestbo J, Knudsen KM, Rasmussen FC. Are respiratory symptoms and chronic airflow limitation really associated with an increased risk of respiratory cancer? Int J Epidemiol 1991; 20: 375-378.
27. Van den Eeden SK, Friedman GD. Forced expiratory volume (1 second) and lung cancer incidence and mortality. Epidemiology 1992; 3: 253-257.
28. Chau N, Benamghar L, Pham QT, Teculescu D, Rebstock E, Mur JM. Mortality of iron miners in Lorraine (France): relations between lung function and respiratory symptoms and subsequent mortality [resumen]. Br J Ind Med 1993; 50: 1017-1131.
29. Carta P, Cocco P, Picchiri G. Lung cancer mortality and airways obstruction among metal miners exposed to silica and low levels of radon daughters. Am J Ind Med 1994; 25: 489-506.
30. 1 and chronic productive cough in cigarette smokers: a 25-year prospective study of lung cancer incidence in Tecumseh, Michigan. Cancer Epidemiol Biomarkers Prev 1994; 3: 289-298.
31. 1. The Lung Health Study. JAMA 1994; 272: 1497-1505.
32. Petty TL. Lung cancer and chronic obstructive pulmonary disease. Med Clin North Am 1996; 80: 645-655.
33. Petty TL. The predictive value of spirometry. Identifying patients at risk for lung cancer in the primary care setting. Postgrad Med 1997; 101: 128-140.
34. Assennato G, Ferri G. Correlazione fra broncopneumopatie croniche e carcinoma del polmone. Arch Monaldi 1989; 44: 689-692.
35. Menard O, Dousset B, Jacob B, Anthoine D, Martinet Y. Signification des taux d'antigène carcino-embryonnaire dans le liquide de lavage alvéolaire en pathologie bronchopulmonaire cancéreuse et non cancéreuse. Rev Mal Resp 1992; 9: 185-189.
36. Sanguinetti CM, Riccioni G, Marchesani F, Pela R, Cecarini L. Bronchoalveolar lavage fluid level of carcynoembryonic antigen in the diagnosis of peripheral lung cancer. Monaldi Arch Chest Dis 1995; 50: 177-182.
37. Anderson D, Hughes JA, Cebulska-Wasilewska A, Nizankowska E, Graca B. Ras p21 protein levels in human plasma from patients with chronic obstructive pulmonary disease (COPD) compared with lung cancer patients and healthy controls. Mutat Res 1998; 403: 229-235.
38. Cohen BH, Graves CG, Kreiss P, Levy DA, Menkes HA, Pernutt S. A common familial component in lung cancer and chronic obstructive pulmonary disease. Lancet 1977; ii: 523-526.
39. Khoury MJ, Beaty TH, Newill CA, Bryant S, Cohen BH. Genetic-environmental interactions in chronic airways obstruction. Int J Epidemiol 1986; 15: 64-71.
40. Saetta M, Baraldo S, Corbino L, Turato G, Braccioni F, Rea F et al. CD8+ve cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 711-717.
41. Saetta M, Di Stefano A, Turato G, Facchini FM, Corbino L, Mapp CE et al. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 822-826.
42. Díez Herranz A. Significado pronóstico de las pruebas inmunológicas en la cirugía del cáncer de pulmón [Tesis doctoral]. Universidad de Valladolid, 1994.
43. Zyrianov BN, Podoplekin VD, Siianov VS, Kuznetsova TI, Tuzikov SA. The determination of the level of antibodies to Epstein-Barr virus antigens in organizing groups at high risk for lung cancer disease [resumen]. Vopr Onkol 1990; 36: 545-549.
44. Palacios A, Escó R, Galán CJ, Sanz JJ, Castillo A, Marín F. Sintomatología inicial y tiempo de diagnóstico del cáncer de pulmón. Aten Primaria 1986; 3: 211-213.
45. Ringbaek T, Borgeskov S, Lange P, Viskum K. Diagnostic and therapeutic process and prognosis in suspected lung cancer. Scand Cardiovasc J 1999; 33: 337-343.
46. Spiro SG, Hansen HH. Early detection: screening. En: Hoogstraten B, Addis BJ, Hansen HH, Martini N, Spiro SG, editores. Lung tumors. Lung, mediastinum, pleura, and chest wall. Berlín: Springer-Verlag, 1988; 9-11.
47. Bolliger CT, Haeussinger K. Early detection of lung cancer. Eur Respir Mon 1998; 9: 22-35.
48. Fontana RS, Sanderson DR, Woolner LW, Taylor WF, Miller WE, Mulim JE et al. Screening for lung cancer. A critique of the Mayo Lung Project. Cancer 1991; 67: 1155-1164.
49. Eddy DM. Screening for lung cancer. Ann Intern Med 1989; 111: 232-237.
50. Salomaa E-R, Liippo K, Taylor P, Palmgren J, Haapakoski J, Virtano J et al. Prognosis of patients with lung cancer found in a single chest radiograph screening. Chest 1998; 114: 1514-1518.
51. Strauss GM, Gleason RE, Sugarbaker DJ. Chest X-ray screening improves outcome in lung cancer. A reappraisal of randomized trials on lung cancer screening. Chest 1995; 107: S270-S279.
52. Strauss GM, Gleason RE, Sugarbaker DJ. Screening for lung cancer. Another look; a different view. Chest 1997; 111: 754-768.
53. Strauss GM. Measuring effectiveness of lung cancer screening. From consensus to controversy and back. Chest 1997; 112: S216-S228.
54. Flehinger BJ, Kimmel M, Pulyak T, Melamed MR. Screening of lung cancer - The Mayo Project revisited. Cancer 1993; 72: 1573-1580.
55. Davis MP. There and back again. Lung cancer screening. Chest 1997; 111: 532-534.
56. Mulshine JL, Scott F. Molecular markers in early cancer detection. New screening tools. Chest 1995; 107: S280-S286.
57. Lam S, Shibuya H. Early diagnosis of lung cancer. Clin Chest Med 1999; 20: 53-61.
58. Skillrud DM COPD: causes, treatment, and risk for lung cancer. Compr Ther 1986; 12: 13-16.
59. 1) - A respiratory physiological measurement of considerable prognostic value [resumen]. Ugeskr Laeger 1991; 153: 2292-2295.
60. Ferguson GT, Enright PL, Buist AS, Higgins MW. Office spirometry for lung health assessment in adults. A consensus statement from the National Health Education Program. Chest 2000; 117: 1146-1161.
61. Petty TL. Lung cancer screening. Compr Ther 1995; 21: 432-437.
62. Böcking A, Biesterfeld S, Chatelain R, Gien Gerlach G, Esser E. Diagnosis of bronchial carcinoma on sections of paraffin-embedded sputum. Sensitivity and specificity of an alternative to routine cytology. Acta Cytol 1992; 36: 37-47.
63. Bechtel JJ, Kelley WR, Petty TL, Patz DS, Saccomanno G. Outcome of 51 patients with roentgenographically occult lung cancer detected by sputum cytologic testing: a community hospital program. Arch Intern Med 1994; 154: 975-980.
64. Kennedy TC, Miller Y, Prindiville S. Screening for lung cancer revisited and the role of sputum cytology and fluorescence bronchoscopy in a high-risk group. Chest 2000; 117: S72-S79.
65. Mehta AC, Marty JR, Lee FYW. Sputum cytology. Clin Chest Med 1993; 14: 69-85.
66. Callol Sánchez L, Gómez de Terreros y Sánchez FJ. Diagnóstico precoz del cáncer de pulmón. Arch Bronconeumol 1999; 35: 395-403.
67. Tockman MS. Advances in early detection of lung cancer. Semin Respir Crit Care Med 1996; 17: 335-341.
68. Tredaniel J, Stucker I, Migaud I, Hirsch A. Depistage du cancer bronchique. Realites et perspectives. Rev Mal Respir 1991; 8: 543-550.
69. Lam S, LeRiche JC, Zheng Y, Coldman A, McAulay C, Hawk E et al. Sex-related differences in bronchial epitelial changes associated with tobacco smoking. J Natl Cancer Inst 1999; 91: 691-696.
70. Lyubsky S, Jacobson MJ. Lung cancer. Making the diagnosis. Chest 1991; 100: 511-520.
71. Kennedy TC, Proudfoot SP, Franklin WA, Merrick TA, Saccomanno G, Corkill ME et al. Cytopathological analysis of sputum in patients with airflow obstruction and significant smoking histories. Cancer Res 1996; 56: 4673-4678.
72. Groenendijk RP, Croiset van Uchelen FA, Mol SJ, de Munck DR, Tan AT, Roumen RM. Factors related to outcome after pneumonectomy: retrospective study of 62 patients. Eur J Surg 1999; 165: 193-197.
73. Miyoshi S, Nakahara K, Ohno K, Monden Y, Kawashima Y. Exercise tolerance test in lung cancer patients: the relationship between exercise capacity and postthoracotomy hospital mortality. Ann Thorac Surg 1987; 44: 487-490.
74. Schulz C, Emslander HP, Riedel M. Risk assessment of patients before lung surgery [resumen]. Chirurg 1999; 70: 664-673.
75. Bründler H, Chen S, Perruchoud AP. Right heart catheterization in the pre-operative evaluation of patients with lung cancer. Respiration 1985; 48: 261-268.
76. Bechard D, Wetstein L. Assessment of exercise oxygen consumption as preoperative criterion for lung resection. Ann Thorac Surg 1987; 44: 344-349.
77. Smith TP, Kinasewitz GT, Tucker WY, Spillers WP, George RB. Exercise capacity as a predictor of post-thoracotomy morbidity. Am Rev Respir Dis 1984; 129: 730-734.
78. Olsen GN, Weiman DS, Bolton JW, Gass GD, McLain WC, Schoonover GA et al. Submaximal invasive exercise testing and quantitative lung scanning in the evaluation for tolerance of lung resection. Chest 1989; 95: 267-273.
79. Morice RC, Peters EJ, Ryan MB, Putnam JB, Ali MK, Roth JA. Exercise testing in the evaluation of patients at high risk for complications from lung resection. Chest 1992; 101: 356-361.
80. Kearney DJ, Lee TH, Reilly JJ, DeCamp MM, Sugarbaker DJ. Assessment of operative risk in patients undergoing lung resection. Importance of predicted pulmonary function. Chest 1994; 105: 753-759.
81. Reilly JJ Jr. Evidence-based preoperative evaluation of candidates for thoracotomy. Chest 1999; 116 (Supl): S474-S476.
82. Ojo TC, Martínez F, Paine R III, Christensen PJ, Curtis JL, Weg JG et al. Lung volume reduction surgery alters management of pulmonary nodules in patients with severe COPD. Chest 1997; 112: 1494-1500.
83. Allen GM, DewRose JJ Jr. Pulmonary nodule resection during lung volume reduction surgery [resumen]. AORN J 1997; 66: 808-810, 812, 814.
84. McKenna RJ Jr, Fischel RJ, Brenner M, Gelb AF. Combined operations for lung volume reduction surgery and lung cancer. Chest 1996; 110: 885-888.
85. Miller JI Jr. Limited resection of bronchogenic carcinoma in the patient with impaired pulmonary function. Ann Thorac Surg 1993; 56: 769-771.
86. Weissberg D, Straehley CJ, Scully NM, Margulies DR. Less than lobar resections for bronchogenic carcinoma. Scand J Thorac Cardiovasc Surg 1993; 27: 121-126.
87. 87: Shennib HA, Landreneau R, Mulder DS, Mack M. Video-assisted thoracoscopic wedge resection of T1 lung cancer in high-risk patients. Ann Surg 1993; 218: 555-558.
88. Wakabayashi A. Thoracoscopic partial lung resection in patients with severe chronic obstructive pulmonary disease. A preliminary report. Arch Surg 1994; 129: 940-943.
89. Korst RJ, Ginsberg RJ, Ailawadi M, Bains MS, Downey RJ Jr, Rusch VW et al. Lobectomy improves ventilatory function in selected patients with severe COPD. Ann Thorac Surg 1998; 66: 898-902.
90. Carretta A, Zannini P, Puglisi A, Chiesa G, Vanzolli A, Bianchi A. Improvement of pulmonary function after lobectomy for non-small cell lung cancer in emphysematous patients [resumen]. Eur J Cardiothorac Surg 1999; 15: 602-607.
91. Berggren H, Ekroth R, Malmberg G, Naucler J, William-Olsson G. Hospital mortality and long-term survival in relation to preoperative function in elderly patients with bronchogenic carcinoma. Ann Thorac Surg 1984; 38: 633-636.
92. Keagy BA, Schorlemmer GR, Murray GF, Stareck PJK, Wilkox BR. Correlation of preoperative pulmonary function testing with clinical course in patients after pneumonectomy. Ann Thorac Surg 1983; 36: 253-257.
93. Koizumi K, Tanaka S, Haraguchi S, Matsushima S, Gomibuchi M. Evaluation of the prognosis of patients with stage I non-small cell lung cancer with respect to predicted postoperative lung function [resumen]. Nippon Kyobu Geka Gakkai Zasshi 1996; 44: 162-168.